antileukotriene

(redirected from Leukotriene antagonist)
Also found in: Acronyms, Wikipedia.

an·ti·leu·ko·tri·ene

(an'tē-lū'kō-trī'ēn),
A drug that prevents or alleviates bronchoconstriction in asthma by blocking the production or action of naturally occurring leukotrienes; may also be useful in psoriasis.

Leukotrienes are eicosanoids derived from arachidonic acid, which is present in cell membranes. The cysteinyl leukotrienes, which are elaborated by bronchopulmonary mast cells, eosinophils, and probably alveolar macrophages, have been shown to mediate bronchoconstriction induced by exercise, hyperventilation in cold air, aspirin, and inhaled allergens. They act by stimulating a specific receptor, known as cysteinyl leukotriene receptor type 1 (CysLT1). Antileukotrienes having clinical usefulness in asthma include zileuton, which inhibits 5-lipoxygenase, an enzyme critical in the biosynthesis of leukotrienes, and leukotriene receptor antagonists (cinalukast, montelukast, zarirlukast, and others). Antileukotrienes reverse bronchconstriction in asthma to a lesser degree than β2-adrenergic agonists, but their effects are additive to those of the latter agents. In chronic asthma, antileukotrienes improve peak flow and FEV1 and reduce the frequency and severity of acute asthmatic attacks, the need for β2-agonists, and the need for corticosteroid rescue. They are particularly effective in the prophylaxis of asthma induced by exercise and aspirin. In contrast, many people with allergic asthma show little or no response. Antileukotrienes are not indicated in the treatment of an acute asthmatic attack or in mild, intermittent asthma controlled adequately with occasional use of inhaled β2-agonists. They have not been recommended as a substitute for inhaled corticosteroids in prophylaxis of asthma. Antileukotrienes are administered orally or by inhalation. Both onset and waning of clinical effects are gradual. Side-effects are minimal, but drug interactions may occur because of interference with cytochrome P-450 enzymes. Rare transitory elevations of hepatic aminotransferase have been reported with some agents.

antileukotriene

Any of a class of agents that either interferes with leukotriene synthesis or antagonises leukotriene receptors, which are as effective as cromolyn or theophylline, and may reduce the amount of inhaled steroids needed to control inflammation.

Antileukotrienes 
LTD4 receptor antagonists (Zafirkulast-Accolate)
 
Pros
LTD4-induced bronchoconstriction, early and late responses, exercise challenge, cold-induced asthma, chronic asthma.
 
5-Lipoxygenase inhibitor (Zileutron-Zyflo)
 
Pros
Asthma induced by exercise, cold, aspirin, bronchial hyperresponsiveness.
 
FLAP inhibitors (5-lipoxygenase-activating protein inhibitor)

Pros
Early and late responses and cold-induced asthma.

antileukotriene

Any of a class of agents that either interfere with leukotriene synthesis or antagonize leukotriene receptors, which are as effective as cromolyn or theophylline, and may ↓ the amount of inhaled steroids needed to control inflammation See Asthma, Leukotrienes, Zafirlukast, Zileuton.
Antileukotrienes
LTD4 receptor antagonists
Zafirkulast-Accolate® Benefits LTD4-induced bronchoconstriction, early and late responses, exercise challenge, cold-induced asthma, chronic asthma
5-Lipoxygenase inhibitor
Zileutron-Zyflo®Benefits asthma induced by exercise, cold, aspirin, bronchial hyperresponsiveness
FLAP inhibitors
None are FDA-approved Benefits early and late responses and cold-induced asthma
.

an·ti·leu·ko·tri·ene

(an'tē-lū-ko-trī'ēn)
A drug that prevents or alleviates bronchoconstriction in asthma by blocking the production or action of naturally occurring leukotrienes; may also be useful in psoriasis.

an·ti·leu·ko·tri·ene

(an'tē-lū-ko-trī'ēn)
A drug that prevents or alleviates bronchoconstriction in asthma by blocking the production or action of naturally occurring leukotrienes; may also be useful in psoriasis.
References in periodicals archive ?
Data Source: Two parallel, multicenter "pragmatic" trials to assess the real-world effectiveness of leukotriene antagonists compared with inhaled glucocorticoids as first-line treatment and compared with long-acting beta-agonists as add-on therapy for poorly controlled asthma.
D] Do not commence leukotriene antagonists during pregnancy.
In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: short acting beta 2 agonists, inhaled corticosteroids, combination therapies and leukotriene antagonists.
1,2) Additional features of the leukotriene antagonists are that they are given orally, thus avoiding any potential patient adherence problems with the use of inhaler devices, but also providing systemic activity and hence suppressing inflammation throughout the airway, including inflammation in the smaller airways.
Currently the treatment of asthma/COPD favors the use of beta-2 agonists and inhaled corticosteroids, with leukotriene antagonists and anticholinergics being positioned as additional therapies in either pediatric or last-line patients.
To calculate the market size, the report considers the revenue generated from the sales of various class of drugs used in the treatment of asthma: - Bronchodilators - Leukotriene antagonists - Mast cell stabilizers - Immunosuppressants TechNavio's report, the Global Asthma Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts.
The leukotriene antagonists are usually well tolerated and in some asthmatics can provide significant benefit.
All of them were using inhaled corticosteroids, but none used theophylline, nasal steroids, leukotriene antagonists, or [H.
Global asthma/COPD sales should grow to $23 billion by 2014, with inhaled corticosteroid/long-acting bronchodilator combinations set to be the leading class by value in 2014, followed by leukotriene antagonists, and anticholinergics.
Conte's second-line treatment approach includes alteration of diet, corticosteroids, the H2 antagonists cimetidine (Tagamet) or ranitidine (Zantac), doxepin, nifedipine, PUVA, warfarin, and leukotriene antagonists.
Outlook for the asthma/COPD market, including key events impacting combination products, leukotriene antagonists, and anticholinergics
Our research reveals that physicians throughout the major markets are accepting the recommendations of evidence-based treatment guidelines that encourage the use of inhaled corticosteroids, corticosteroid/beta2 agonists, and leukotriene antagonists as daily prophylactic therapy for asthma.